This article has Open Peer Review reports available.
Down-regulatory mechanism of mammea E/BB from Mammea siamensis seed extract on Wilms’ Tumor 1 expression in K562 cells
© Rungrojsakul et al. 2016
Received: 16 January 2016
Accepted: 5 May 2016
Published: 18 May 2016
Wilms’ tumor 1 (WT1) is a biological marker for predicting leukemia progression. In this study, mammea E/BB, an active compound from Saraphi (Mammea siamensis) seed extract was examined for its effect on down-regulatory mechanism of WT1 gene expression, WT1 protein and mRNA stability, and cell proliferation in K562 cell line.
M. siamensis seeds were obtained from the region of Chiang Mai (North of Thailand). Mammea E/BB was extracted from seeds of M. siamensis. WT1 protein expression and stability were evaluated by Western blot analysis. WT1 mRNA stability was assessed by qRT-PCR. WT1-DNA binding and WT1 promoter activity were assayed by ChIP assay and luciferase-reporter assay, respectively. Cell cycle arrest was studied by flow cytometry.
Treatment with mammea E/BB led to down-regulation of WT1 expression. The suppression of WT1 expression did not involve protein and mRNA degradation. Rather, WT1 protein was down-regulated through disruption of transcriptional auto-regulation of the WT1 gene. Mammea E/BB inhibited WT1-DNA binding at the WT1 promoter and decreased luciferase activity. It also disrupted c-Fos/AP-1 binding to the WT1 promoter via ERK1/2 signaling pathway and induced S phase cell cycle arrest in K562 cells.
Mammea E/BB had pleotropic effects on kinase signaling pathways, resulting in inhibition of leukemia cell proliferation.
The Wilms’ tumor 1 (WT1) gene is located at chromosome 11p13 and encodes a 48–57 kDa WT1 protein that functions as a DNA-binding transcription factor involved in growth regulation, and is necessary for the induction of cell differentiation . WT1 has been purported to have both oncogenic and tumor suppressor functions. Low levels of WT1 protein expressions have been found in normal blood cells, while high levels of WT1 protein have been found in leukemia patients . Previously, pure curcumin was shown to repress WT1 gene expression in both primary and leukemic cells . In addition, Semsri et al. reported that pure turmeric curcumin affected WT1 protein-promoter binding and decreased WT1 mRNA and protein levels through inhibition of the PI3K/PKCα/JNK pathway in K562 cells . Moreover, expression of the WT1 gene and its product has been used as biological markers for diagnosis and evaluation of the prognosis in leukemia and minimal residual disease (MRD) [18, 21]. A previous study revealed that mammea E/BB also suppressed WT1 protein expression when compared to surangin A and surangin C . However, the down-regulatory mechanism was unknown. The current study therefore aimed to examine the inhibitory mechanism of mammea E/BB on WT1 gene expression, WT1 protein and mRNA stability, and cell proliferation in K562 cell line.
M. siamensis seeds were collected from Chiang Mai University, Amphoe Muang, Chiang Mai province, Thailand in May 2010. The plant material used in this study was identified by Mr. James Franklin Maxwell. A voucher specimen (J.F. Maxwell, No.92-70) is deposited in the CMU herbarium, Faculty of Science, Chiang Mai University, Chiang Mai, Thailand. RPMI-1640, fetal bovine serum, L-glutamine, penicillin/streptomycin, Quick-Change Site Mutagenesis Kit, and HRP-conjugated goat anti-rabbit IgG were purchased from Invitrogen™ Life (Carlsbad, CA, USA). MTT dye and StaphA cells were purchased from Sigma-Aldrich (St Louis, MO, USA). Trypan blue dye solution was purchased from AMRESCO® (Solon, OH, USA). Rabbit anti-WT1 and rabbit anti-GAPDH was purchased from Santa Cruz Biotechnology (CA, USA). Rabbit anti-p-ERK1/2 was purchased from New England BioLabs (Beverly, MA, USA). Mouse anti-cyclin B and Mouse anti-cyclin A were purchased from BD Transduction Laboratories™ (USA). Mouse anti-CDK1 (cdc2) was purchased from Abcam® (MA, USA). Rabbit anti-c-Fos and PathScan® Intracellular Signaling Array Kit (Chemiluminescent Readout) were purchased from Cell Signaling Technology® (Danvers, MA, USA). HRP-conjugated anti-mouse IgG, Go Taq® DNA Polymerase, Dual-Luciferase Reporter Assay Kit, and β-galactosidase Assay Kit were purchased from Promega (WI, USA). Enhanced chemiluminescence detection kit and Dream Taq Green PCR master mix were purchased from Thermo Scientific (Miami, USA). E.Z.N.A.® Total RNA Kit I was purchased from Omega bio-tek (Norcross, GA, USA). RevertAid First Strand cDNA Synthesis Kit was purchased from Thermo scientific (EU). Cycloheximide (CHX) and actinomycin D were purchased from Calbiochem (USA). Qiaquick PCR kit was purchased from Qiagen (CA, USA).
General experimental procedures
Optical rotations were measured with a JASCO P-1020 polarimeter. 1D and 2D NMR spectra were recorded using a Bruker AVANCE 400 NMR spectrometer. Chemical shifts (δ) are expressed in ppm with reference to the solvent signals. UV spectra were measured using a SHIMADZU UV-2450 spectrophotometer.
Extraction and isolation of mammea E/BB
Mammea E/BB was purified from seeds of M. siamensis using column chromatography, extraction, and isolation as previously described . Mammea E/BB was obtained as a pale yellowish gum with [α] D 27 −65.7° (c = 0.40, MeOH). The UV spectra of mammea E/BB exhibited absorption maxima bands at 337 and 265 nm; these are characteristic for coumarin . The absolute stereochemistry at C-1’ and C-2′′′ was assigned to be S from its negative optical rotation value . The mammea E/BB identity was confirmed by comparison of the 1H and 13C NMR spectra data (Additional file 1: Figure S1 and Additional file 2: Figure S2) with those reported in the literature [24, 25].
Cells and cell culture conditions
The K562 cell line, a model of WT1-overexpressing leukemic cells, was cultured in RPMI-1640 medium supplemented with 10 % fetal bovine serum, 1 mM L-glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin, and incubated under 95 % relative humidity with 10 % CO2 at 37 °C.
The cytotoxicity of mammea E/BB was evaluated using the MTT assay. Briefly, K562 cells (1.0 × 104 cells/well) were cultured in 96 well plates containing 100 μl medium prior to treatment for 24 h. After that, 100 μl of fresh medium containing various concentrations (0–116 μM) of the test compound were added to each well and incubated for 72 h. The MTT dye solution was added and the percent cell viability, IC50, and IC20 values were calculated as previously described .
Trypan blue exclusion assay
Cell proliferation was measured by the trypan blue exclusion method. Cells were treated with various concentrations of mammea E/BB for 72 h. Then cells and 0.4 % trypan blue dye were mixed and counted using a light microscrope. All experiments were performed in triplicate.
Protein extraction and Western blotting
K562 cells were treated with mammea E/BB for 72 h, after which the cells were collected, washed twice with cold PBS, and lysed with cold RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1 % Triton X-100, 0.5 mM EDTA, 0.1 % SDS, and 0.001 % protease inhibitor cocktail) for whole protein extraction. Whole protein lysates (25 μg) were loaded onto 12 % SDS-PAGE and then transferred to PVDF membranes. Membranes were blocked with 5 % skim milk and probed with rabbit anti-WT1, rabbit anti-p-ERK1/2, mouse anti-cyclin B, mouse anti-cyclin A, and mouse anti-CDK1 (cdc2) at 1:1,000 dilution. Rabbit anti-GAPDH at a dilution of 1:1,000 was used for protein loading control. The reaction was followed by HRP-conjugated goat anti-rabbit IgG at 1:10,000 dilution and HRP-conjugated anti-mouse IgG at 1:10,000 dilution. Proteins were visualized using an enhanced chemiluminescence detection kit and the chemiluminescent signals detected using an Alpha Innotech gel imaging system (Cell Biosciences Inc., CA, USA). Densitometry was performed using Alpha Innotech software. The band density of the loading control was used to normalize the band densities of proteins of interest to obtain the relative normalized expression level as compared to the exposed control.
RNA isolation and reverse transcription PCR analysis
K562 cells were treated with mammea E/BB and the cell pellets were collected. The pellets were washed twice with cold PBS and isolated by E.Z.N.A.® Total RNA Kit I according to the manufacture’s protocol. The cDNA (1 μg) was synthesized from total RNAs using a RevertAid First Strand cDNA Synthesis Kit with random hexamer primers according to the manufacture’s instructions. RT-PCR analysis was carried out with a Mastercycler® personal (Eppendorf, CA, USA) instrument with Dream Taq Green PCR master mix probe-based chemistry for WT1 and GAPDH.
Protein degradation and mRNA half-Life analysis
K562 cells were incubated (0, 3, 6, 12, and 24 h) with or without 5 μM MG132 (proteasome inhibitor) and confirmed by 50 μg/ml cycloheximide (CHX) in the presence or absence of 3.5 μM of mammea E/BB. The WT1 mRNA stability of K562 cells was assessed with 4 μM actinomycin D in the presence or absence of 3.5 μM mammea E/BB.
Chromatin immunoprecipitation (ChIP) assay
The concept of chromatin immunoprecipitation or ChIP is an experimental form of immunoprecipitation used to investigate the interaction between proteins and DNA in the cell . Briefly, cells were treated with 3.5 μM mammea E/BB for 72 h then crosslinked with 1 % formaldehyde for 10 min, followed by addition of 0.125 M glycine to stop the crosslinking. Cells were suspended in cell lysis buffer (5 mM PIPE, 85 mM KCl, 1 % NP40, and protease inhibitors), incubated on ice for 15 min and centrifuged at 5,000 rpm at 4 °C for 5 min. The nuclei pellet was resuspended in lysis buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1 % SDS, and protease inhibitors) and incubated on ice for 10 min before sonication. The chromatin lysate was precleared with StaphA cells before immunoprecipitation at 4 °C overnight. Antibodies included WT1 (C-19), c-Fos, and normal rabbit IgG as a negative control. On the following day Staph A cells were added to precipitate the IgG/protein/DNA complex. The StaphA cell pellets were washed extensively, followed by elution and reversal of protein-DNA crosslinking. The protein was removed from the DNA lysate using the Qiaquick PCR kit. Standard PCR was performed on the precipitated DNA template using Go Taq® DNA Polymerase.
The human WT1 promoter sequence was obtained from NCBI, accession # U77682. Primer design for the WT1 promoter region utilized Primer3 Input (version 0.4.0), UCSC Genome Browser and Vector NTI advance 10: WT1 promoter primer sequence No.1 consisted of the forward primer (CTGAACGGACTCTCCAGTG) and reverse primer (CGCTGCCTTGAACTCCTTAC); WT1 promoter primer sequence No.2 consisted of the forward primer (GGCCCCTCTTATTTGAGCTT) and reverse primer (CAAGAGGAA GTCCAGGATCG).
Promoter luciferase-reporter assay
WT1 promoter vectors were a kind gift from Professor Dr. Takashi Murate (Department of Medical Technology, Nagoya University Graduate School of Heath Sciences, Japan). The WT1 promoter sequence, including the WT1 and c-Fos/AP-1 binding site, and 301 bp reporter constructs was inserted into the pGL3 basic vector. For the mutant pGL3 construct, core nucleotides of a potential WT1 binding site were altered using a Quick-Change Site Mutagenesis Kit with PCR primers for the WT1 consensus sequence located at -50 to-39; GTGTGGGAGCC  was mutated to ATATGATATCA. K562 cells were co-transfected with the construct vector and β-galactosidase (β-Gal) for 24 h and then treated with mammea E/BB. Co-transfected cells were lysed with lysis buffer. Luciferase activity of the lysis solution was measured using a Dual-Luciferase Reporter Assay Kit, β-galactosidase Assay Kit and a GloMax 96 Microplate Luminometer with dual injections (Promega, USA).
Intracellular signaling array
The intracellular signaling pathway involved in leukemic cell growth inhibition after treatment was determined using a PathScan® Intracellular Signaling Array Kit (Chemiluminescent Readout).
Cell cycle analysis
Cell cycle analysis was done via flow cytometry using propidium iodide (PI), which represents the content of nuclear DNA. K562 cells (1 × 105 cells/ml) were cultured in complete RPMI-1640 medium with or without mammea E/BB for 72 h. After treatment, cells were washed twice with ice-cold PBS and prepared as a single-cell suspension. Then, the cells were fixed with ice-cold 70 % absolute ethanol for 30 min and harvested by centrifugation. The cell pellets were then washed with ice-cold PBS and stained with PI solution (0.1 % triton X-100, 8 μg/ml RNase A, 2 mM EDTA, and 20 μg/ml PI) in the dark at 4 °C. Thereafter, the red fluorescence was measured on a BD FACSCaibur flow cytometer (Becton Dickinson, San Jose, CA, USA). A minimum of 50,000 events was collected per sample. The data were analyzed using FlowJo 7.6.5 software.
All the data were expressed as the mean ± standard deviation (SD) or mean ± standard error of mean (SEM) from triplicate samples of three independent experiments. The statistical differences between the means were determined using one-way ANOVA. The differences were considered significant when the probability value obtained was found to be less than 0.05 (p < 0.05).
Mammea E/BB decreased WT1 protein levels and total cell number with increasing time and dose in K562 cells
Mammea E/BB induced S phase cell cycle arrest in K562
Effect of mammea E/BB on WT1 protein and WT1 mRNA stability
Mammea E/BB attenuates WT1 auto-regulation
The minimal promoter element essential for WT1 gene expression is the WT1 proximal promoter (-301 bp) . The WT1 (-50 to -39) consensus binding site is included in this proximal promoter element (Fig. 7c). Transfection of this 301 bp construct, contained within the pGL3 reporter vector into K562 cells, demonstrated high luciferase activity in vehicle control treated cells and a diminished response with the various concentrations of mammea E/BB (1.5, 2.5, and 3.5 μM) treated K562 cells (Fig. 7d). As a control, a reporter construct containing a mutated WT1 binding site was included. The mutant vector did not show significantly increased activity compared to the empty pGL3 vector, demonstrating that this assay is mostly driven by WT1 binding.
Mammea E/BB decreases p-ERK1/2 (Thr202/Tyr204) in K562 cells
To date, saraphi (M. siamensis) has been used in Thai folk medicine remedies with limited scientific knowledge, especially regarding its biological activity in leukemic cells. In this study, mammea E/BB (the active compound in M. siamensis seeds) was examined for its down-regulatory mechanism to suppress leukemic cell proliferation via inhibiting WT1 protein expression. Mammea E/BB has been reported to impact cancer cells . It is an important active compound in the nonpolar part of M. siamensis seed extract. The results of the present study demonstrate that mammea E/BB inhibited cell proliferation and repressed WT1 expression in the human leukemia K562 cell line.
The activities of mammea E/BB on WT1 protein expression and total viable cell number were found to decrease with increasing time and dose by Western blotting and trypan blue exclusion method, respectively. There was no difference in the number of dead cells (dead cells accounting for less than 10 %) at each time point between the vehicle control and mammea E/BB treatment.
The effect of various concentrations of mammea E/BB was examined and found to decrease WT1 protein levels in response to 0.125 to 4.5 μM by Western blotting. Moreover, the total cell number was significantly decreased at 72 h by 61.3 ± 8.9 to 89.2 ± 0.8 %, as compared to the vehicle control. The dead cells accounted for less than 10 %. Mammea E/BB treatments led to a decline in K562 leukemia cell number without increasing the number of dead cells, suggesting that growth inhibition is mainly through cell cycle arrest. Thus, the effect of mammea E/BB on cell cycle progression was investigated. Indeed, mammea E/BB treatment (3.5 μM) led to a significant decline in K562 cells in the S phase of the cell cycle as assessed by flow cytometry. Furthermore, the proteins related to S and G2/M phase control were determined. It was found that cell cycle checkpoint proteins (cyclin A, cyclin B, and cdc2) at the S and G2/M phases were significantly decreased in a dose-dependent manner.
This study next examined whether WT1 down-regulation by mammea E/BB was through effects on protein or mRNA degradation pathways. K562 cells occurred treated with 3.5 μM mammea E/BB (IC20) for 24 h in the presence or absence of the proteasome inhibitor MG132. WT1 protein expression decreased similarly after treatment with mammea E/BB in the presence or absence of MG132, indicating that mammea E/BB-mediated down-regulation of WT1 protein was likely not through proteasomal degradation pathways. In addition, WT1 protein half-life was examined using the protein synthesis inhibitor, cycloheximide (CHX). The half-life of WT1 protein after mammea E/BB treatment was not significantly different as compared to the vehicle control, suggesting that mammea E/BB does not accelerate WT1 protein degradation. WT1 mRNA stability was examined using actinomycin D (Act D) treatment in the presence or absence of mammea E/BB. The results demonstrated that mammea E/BB treatment did not significantly alter the decay of WT1 mRNA. Collectively, the results strongly suggest that WT1 repression by mammea E/BB is not through accelerated WT1 protein or mRNA degradation but rather is related to the WT1 signaling pathway.
The experiment further examined whether mammea E/BB impacts the transcriptional regulation in signal transduction of the WT1 gene using the ChIP assay. It was found that treatment of K562 cells with mammea E/BB for 72 h could significantly inhibit WT1 binding to its own promoter by 75 %. WT1 is known to drive its own transcription using an auto-regulatory mechanism. Mammea E/BB also disrupted c-Fos binding to the WT1 promoter. C-Fos/AP-1 is the heterodimeric partner of c-Jun, together creating the AP-1 transcription factor. AP-1 is known to play an important role in cell proliferation  and the WT1 promoter has one AP-1 consensus sequence, TGAGTGA, at +144 to +150. C-Fos/AP-1 must be phosphorylated by MAPK/ERK in order to function as a transcription factor  and mammea E/BB may inhibit c-Fos/AP-1 recruitment to the WT promoter by inhibiting ERK1/2 phosphorylation (discussed below).
The minimal promoter element that is essential for WT1 gene expression is the WT1 proximal promoter (-301 bp) . The WT1 consensus binding site (-50 to -39) is included in this proximal promoter element. Transfection of this 301 bp construct, contained within the pGL3 reporter vector into K562 cells demonstrated high luciferase activity with vehicle control treated cells and a diminished response with the various concentrations of mammea E/BB (1.5, 2.5, and 3.5 μM). As a control, a reporter construct containing a mutated WT1 binding site was included. The mutant vector did not show significantly increased activity compared to the empty pGL3 vector, demonstrating that this assay is mostly driven by WT1 binding.
Mammea E/BB had varying effects on WT1 signaling in K562 cells and led to a significant decrease in p-ERK1/2 phosphorylation. Given the wide-ranging roles for ERK1/2 in cell proliferation and survival, inhibition of ERK1/2 phosphorylation may contribute to mammea E/BB’s biological activity. These findings demonstrate that mammea E/BB decreased WT1 protein expression and induced S phase cell cycle arrest in leukemia cells. This study uses an in vitro experimental model and will be further studied in an animal models and clinical trials. In the previous study, WT1 expression in patient leukemic cells was determined after turmeric curcumin treatment and WT1 mRNA was decreased after treatment, especially in patients with a high level of WT1 gene expression patients .
The current study has demonstrated that pure mammea E/BB-mediated down-regulation of WT1 was not the result of protein or mRNA degradation processes. Rather, both chromatin immunoprecipitation (ChIP) and luciferase reporter assays indicate that mammea E/BB interferes with WT1 and c-Fos/AP-1 binding to their DNA consensus sites at the proximal promoter of the WT1 gene, nullifying WT1’s positive auto-regulatory role. Therefore, a low dose of mammea E/BB functions to inhibit WT1 expression at the transcriptional regulatory level and induce S phase cell cycle arrest in K562 cells. This novel mechanistic knowledge of how mammea E/BB affects WT1 transcriptional function in leukemic cells may be useful in the future development of the natural product for therapeutic treatment of leukemia patients.
Ethics approval and consent to participate
Consent for publication
Availability of data and materials
The datasets supporting the conclusions of this article are included within the article and additional files.
The authors are grateful for grants received from the Chandrakasem Rajabhat University Fund (CRUF), CRUF through the Ph.D. Program of Thailand, The Thailand Research Fund (TRF), Grant number RSA5580029, and the National Research Council (NRC) and Chiang Mai University Research Fund under Grant number 2558A10401001.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Smitinand T. Thai plant names (botanical names-vernacular names). Thailand: Funny Publishing Ltd; 1980.Google Scholar
- Poobrasert O, Constant HL, Beecher CW, Farnsworth NR, Kinghorn AD, Pezzuto JM, et al. Xanthones from the twigs of Mammea siamensis. Phytochemistry. 1998;47(8):1661–3.View ArticlePubMedGoogle Scholar
- Mahidol C, Kaweetripob W, Prawat H, Ruchirawat S. Mammea coumarins from the flowers of Mammea siamensis. J Nat Prod. 2002;65(5):757–60.View ArticlePubMedGoogle Scholar
- Reutrakul V, Leewanich P, Tuchinda P, Pohmakotr M, Jaipetch T, Sophasan S, et al. Cytotoxic coumarins from Mammea harmandii. Planta Med. 2003;69(11):1048–51.View ArticlePubMedGoogle Scholar
- Subhadhirasakul S, Pechpongs P. A terpenoid and two steroids from the flowers of Mammea siamensis. Songklanakarin J Sci Technol. 2005;27 Suppl 2:555–61.Google Scholar
- Laphookhieo S, Syers JK, Kiattansakul R, Chantrapromma K. Cytotoxic and antimalarial prenylated xanthones from cratoxylum cochinchinense. Chem Pharm Bull (Tokyo). 2006;54(5):745–7.View ArticleGoogle Scholar
- Laphookhieo S, Promnart P, Syers JK, Kanjana-Opas A, Ponglimanont C, Karalai C. Coumarins and xanthones from the seeds of mammea siamensis. J Braz Chem Soc. 2007;18(5):1077–80.View ArticleGoogle Scholar
- Prachyawarakorn V, Mahidol C, Ruchirawat S. Pyranocoumarins from the twigs of mammea siamensis. Phytochemistry. 2006;67(9):924–8.View ArticlePubMedGoogle Scholar
- Ngo NT, Nguyen VT, Vo HV, Vang O, Duus F, Ho TD, et al. Cytotoxic coumarins from the bark of mammea siamensis. Chem Pharm Bull (Tokyo). 2010;58(11):1487–91.View ArticleGoogle Scholar
- Tung NH, Uto T, Sakamoto A, Hayashida Y, Hidaka Y, Morinaga O, et al. Antiproliferative and apoptotic effects of compounds from the flower of mammea siamensis (Miq.) T. Anders. On human cancer cell lines. Bioorg Med Chem Lett. 2013;23(1):158–62.View ArticlePubMedGoogle Scholar
- Issakul K, Jatisatienr A, Pawelzik E, Jatisatienr C. Potential of mammea siamensis as a botanical insecticide: its efficiency on diamondback moth and side effects on non-target organisms. J Med Plant Res. 2011;5(11):2149–56.Google Scholar
- Yang H, Protiva P, Gil RR, Jiang B, Baggett S, Basile MJ, et al. Antioxidant and cytotoxic isoprenylated coumarins from mammea americana. Planta Med. 2005;71(9):852–60.View ArticlePubMedGoogle Scholar
- Morikawa T, Sueyoshi M, Chaipech S, Matsuda H, Nomura Y, Yabe M, et al. Suppressive effects of coumarins from mammea siamensis on inducible nitric oxide synthase expression in RAW264.7 cells. Biorg Med Chem. 2012;20(16):4968–77.View ArticleGoogle Scholar
- Deng Y, Nicholson RA. Antifungal properties of surangin B, a coumarin from mammea longifolia. Planta Med. 2005;71(4):364–5.View ArticlePubMedGoogle Scholar
- Okokon JE, Udokpoh AE, Essiet GA. Antimalarial activity of mammea Africana. Afr J Tradit Complement Altern Med. 2006;3(4):43–9.Google Scholar
- Olmedo D, Sancho R, Bedoya LM, López-Pérez JL, del Olmo E, Muñoz E, et al. 3-Phenylcoumarins as inhibitors of HIV-1 replication. Molecules. 2012;17(8):9245–57.View ArticlePubMedGoogle Scholar
- Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med. 2007;9(14):1–17.View ArticlePubMedGoogle Scholar
- Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84(9):3071–9.PubMedGoogle Scholar
- Anuchapreeda S, Tima S, Duangrat C, Limtrakul P. Effect of pure curcumin, demethoxycurcumin, and bisdemethoxycurcumin on WT1 gene expression in leukemic cell lines. Cancer Chemother Pharmacol. 2008;62(4):585–94.View ArticlePubMedGoogle Scholar
- Semsri S, Krig SR, Kotelawala L, Sweeney CA, Anuchapreeda S. Inhibitory mechanism of pure curcumin on Wilms’ tumor 1 (WT1) gene expression through the PKCalpha signaling pathway in leukemic K562 cells. FEBS Lett. 2011;585(14):2235–42.View ArticlePubMedGoogle Scholar
- Guo X, Xu S, Dong Z. WT1 gene expression in leukemia patients and its correlation with prognosis and multidrug resistance. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 1999;20(2):69–72.PubMedGoogle Scholar
- Rungrojsakul M, Saiai A, Ampasavate C, Anuchapreeda S, Okonogi S: Inhibitory effect of mammea E/BB from Mammea siamensis seed extract on Wilms’ tumour 1 protein expression in a K562 leukaemic cell line. Nat Prod Res. 2016;30(4):443–7.Google Scholar
- Du L, Mahdi F, Jekabsons MB, Nagle DG, Zhou YD. Natural and semisynthetic mammea-type isoprenylated dihydroxycoumarins uncouple cellular respiration. J Nat Prod. 2011;74(2):240–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Laphookhieo S, Maneerat W, Kiattansakul R. Phenolic compounds from mammea siamensis seeds. Canadian J Chemistry-Revue Canadienne De Chimie. 2006;84(11):1546–9.View ArticleGoogle Scholar
- Du L, Mahdi F, Jekabsons MB, Nagle DG, Zhou YD. Mammea E/BB, an isoprenylated dihydroxycoumarin protonophore that potently uncouples mitochondrial electron transport, disrupts hypoxic signaling in tumor cells. J Nat Prod. 2010;73(11):1868–72.View ArticlePubMedPubMed CentralGoogle Scholar
- O’Geen H, Nicolet CM, Blahnik K, Green R, Farnham PJ. Comparison of sample preparation methods for ChIP-chip assays. BioTechniques. 2006;41(5):577–80.View ArticlePubMedPubMed CentralGoogle Scholar
- Fraizer GC, Wu YJ, Hewitt SM, Maity T, Ton CC, Huff V, et al. Transcriptional regulation of the human Wilms’ tumor gene (WT1). Cell type-specific enhancer and promiscuous promoter. J Biol Chem. 1994;269(12):8892–900.PubMedGoogle Scholar
- Yagi N, Ohkubo K, Okuno Y, ODA Y, MIYAZAWA M. Antimutagenic compound from yellow batai (Peltophorum dasyrachis). J Oleo Sci. 2006;55(4):173–80.View ArticleGoogle Scholar
- Herrera R, Agarwal S, Walton K, Satterberg B, Distel RJ, Goodman R, et al. A direct role for c-fos in AP-1-dependent gene transcription. Cell Growth Differ. 1990;1(10):483–90.PubMedGoogle Scholar
- Wang Y, Prywes R. Activation of the c-fos enhancer by the erk MAP kinase pathway through two sequence elements: the c-fos AP-1 and p62TCF sites. Oncogene. 2000;19(11):1379–85.View ArticlePubMedGoogle Scholar
- Anuchapreeda S, Limtrakul P, Thanarattanakorn P, Sittipreechacharn S, Chanarat P. Inhibitory effect of curcumin on WT1 gene expression in patient leukemic cells. Arch Pharm Res. 2006;29(1):80–7.View ArticlePubMedGoogle Scholar